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type iii, iV, and Vi collagens 
turnover in Systemic Sclerosis – a 
Longitudinal Study
pernille Juhl  1,2 ✉, Anne-christine Bay-Jensen2, Roger Hesselstrand3, Anne S. Siebuhr2 & 
Dirk M. Wuttge3
tissue turnover, especially in the skin, is altered in systemic sclerosis (SSc), leading to tissue 
accumulation. the objective was to examine type iii, iV, and Vi collagens turnovers in SSc and 
investigate longitudinal alterations in relation to modified Rodnan Skin Score (mRSS). We included 
patients fulfilling the 2013 ACR/EULAR criteria for SSc (limited cutaneous [lcSSc, n = 20], diffuse 
cutaneous SSc [dcSSc, n = 23]) and healthy controls (HC, n = 10). Biomarkers of type III, IV, and VI 
collagens formation (PRO-C3, PRO-C4, PRO-C6) and degradation (C3M, C4M, C6M) were measured in 
serum. The fibrotic index of the individual collagens (FICol) were calculated. The fibrotic index of type 
III and VI collagens (FICol3 and FICol6) were increased in dcSSc compared to lcSSc (FICol3: 1.4 vs. 0.8, 
p = 0.0001; FICol6: 1.2 vs. 0.9, P = 0.03). The fibrotic index of type IV collagen (FICol4) was not different 
between the groups but was 1.5 times higher than HC (HC: 6.9, lcSSc 10.4, dcSSc: 10.5). Both FICol3 
and FICol6 correlated with mRSS with rho’s of 0.59 (P < 0.0001) and 0.35 (P = 0.04). Furthermore, 
FICol3 steadily decrease over the disease course. Examining collagen turnover and specific collagens 
could be beneficial in following patients’ skin fibrosis and possibly identifying progressors.
Systemic sclerosis (SSc) is a dynamic disease in which the literature suggests that microvascular damage leads 
to damage to endothelial cells resulting in fibrosis by activation of fibroblasts1,2. Fibrosis is both seen around the 
blood vessels and in the deeper interstitial matrix of the affected tissues. The majority of SSc patients have skin 
fibrosis, whereas some have fibrosis of various internal organs. The extent of skin fibrosis is used to divide patients 
into two subgroups; limited cutaneous SSc (lcSSc) and diffuse cutaneous SSc (dcSSc)3.
Fibrosis is the result of a tilted remodelling of the extracellular matrix (ECM). Fibroblasts, together with other 
cells, are responsible for maintaining the ECM by ensuring that damaged proteins, such as collagens, are degraded 
and replaced by new collagens. If fibroblasts are continuously activated, they will differentiate into myofibroblasts 
and produce more ECM proteins than needed resulting in fibrosis.
Collagens are the most abundant protein group in the body, where different collagens have different roles and 
locations. The synthesis of collagen is known to be upregulated in SSc, and the focus of the literature has primarily 
been on the two main collagens found in skin; type I and III collagens. These are usually found in the interstitial 
matrix, where they act as the “skeleton” of tissue as the skin. Other collagens as type VI collagen is furthermore 
found in the interstitial matrix of the skin where it is implicated in matrix organization and fibrillogenesis of col-
lagens4. Type VI collagen gene and protein levels have been shown upregulated in SSc5,6. The ECM composition 
of the basement membrane around blood vessels differs from the interstitial matrix. The basement membrane 
mainly consists of type IV collagen and laminin compared to the type I and III collagens-rich interstitial mem-
brane. Type VI collagen is primarily found in the intersection between the basement membrane and interstitial 
matrix and throughout both sections. Knowledge of different collagens can help understand the location of the 
fibrosis and target specific types of fibrosis.
The study aimed to examine collagen turnover in SSc patients by investigating the level of formation and deg-
radation of ECM metabolites in blood. Furthermore, we studied the change in collagen turnover over time and in 
relation to the modified Rodnan Skin Score (mRSS).
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patients and Methods
Study population. In this cross-sectional and longitudinal pilot study, we included 43 SSc patients fulfill-
ing the 2013 ACR/EULAR criteria7. Twenty patients had lcSSc and 23 patients fulfilled the criteria for dcSSc3. 
All patients had multiple visits to the department of rheumatology, Skåne university hospital-Lund (3–11 vis-
its) where blood samples and clinical features were obtained8. Non-medicated asymptomatic controls (n = 10) 
were included. Serum samples were collected and stored at −80 °C until measured. The study was approved by 
the Swedish Ethical Review Authority in Lund (approval number Dnr 590/2008) and carried out following the 
Declaration of Helsinki. All participants had given written, informed consent.
Serological protein fingerprint biomarkers for ECM turnover. ECM turnover was examined by 
assessing biomarkers of type III, IV, and VI collagens formation (PRO-C39, PRO-C410, and PRO-C611, respec-
tively) and degradation (C3M12, C4M13 and C6M14, respectively) (produced by Nordic Bioscience). Validated 
competitive ELISAs assessed analytes according to the manufacture’s protocols. Measurements below the lower 
limit of detection were assigned the value of the lower limit of detection.
The turnover (fibrotic index) was calculated to examine collagen deposition. It was calculated by dividing the 
collagen formation with the degradation biomarker.
=
−Type x formation PRO Cx
Type x degradation CxM
Fibrotic index of type x collagen ( )
)
,
x indicating the collagen number.
Statistics. Summary statistics were used to examine the baseline demographics at their first visit. Data are 
depicted as mean and standard deviation (SD) or numbers and percent (%). As the biomarkers were not normally 
distributed, non-parametric tests were used. The difference in biomarker levels between lcSSc and dcSSc was 
tested by the Mann-Whitney U test and correlations were evaluated by spearman’s correlation. Duration and SSc 
specific differences in the levels of the measurements (mRSS or biomarkers) were analysed using Generalized 
Additive Mixed Models15. We used a quasi-poisson distribution as a model of the probability distribution of 
mRSS measurements, and a gamma distribution as a model of the probability distribution of biomarker meas-
urements. To account for the repeated measurements within patients we used an exchangeable correlation struc-
ture. The expected levels of the measurements were smoothed using thin plate splines with automatic smoothing 
selection16.
For each measurement we consider three nested model
•	 Base model: Smooth effect of duration, no SSc-form differences
•	 General model: Separate smooth effects duration age by the two SSc-forms. The base and general models were 
compared by likelihood-ratio tests to assess the hypothesis of no SSc-form differences in the level and shape 
of the timecourse of the measurements.
The biomarker levels were displayed as mean. P-values ≤ 0.05 were considered statistically significant. 
Graphical illustrations and Mann-Whitney U test were performed using GraphPad Prism version 8, spear-
man’s correlation was analysed by MedCalc statistical software version 18.11.6, and the analyses and graphics of 
Generalized Additive Mixed Models were performed in R version 3.6.117.
Results
The patients were subdivided based on the extent of skin involvement and the demographic data analysed 
(Table 1). The lcSSc subgroup had longer disease duration and lower mRSS, as expected. Otherwise, the two sub-
groups were similar regarding age, BMI, and the patients being predominately females.
collagen turnover in SSc subgroups. Collagen turnover was examined at the first time point to examine 
levels in the two subgroups of SSc. The turnover of type III (FICol3) and VI (FICol6) collagens were increased 
in dcSSc compared to lcSSc (FICol3; lcSSc (mean): 0.8, dcSSc (mean): 1.4, P = 0.0001, FICol6; lcSSc: 0.9, dcSSc: 
1.2, P = 0.03; Fig. 1). For both collagens, the level in lcSSc was similar to healthy controls. Type IV collagen 
turnover (FICol4) was not different between the two SSc subgroups (lcSSc: 10.4, dcSSc: 10.5). However, it was 
approximately 1.5 times higher than in the healthy controls. The collagen turnover is a product of formation and 
degradation. Formation and degradation were also examined separately. Type III and VI collagens formation 
were significantly higher in dcSSc compared to lcSSc (PRO-C3; lcSSc: 31.4 ng/ml, dcSSc: 51.2 ng/ml, P = 0.01, 
PRO-C6; lcSSc: 4.7 ng/ml, dcSSc: 8.2 ng/ml, P = 0.1). Type III collagen degradation was significantly increased in 
lcSSc compared to dcSSc (lcSSc: 17.4 ng/ml, dcSSc: 13.3 ng/ml, P = 0.03) and type VI collagen degradation was 
(lcSSc: 14.3 ng/ml, dcSSc: 18.8 ng/ml) was not different in the two SSc subsets. Type IV collagen formation (lcSSc: 
354.4 ng/ml, dcSSc: 310.3 ng/ml,) showed a tendency for a small increase in lcSSc compared to dcSSc and the 
same was seen in type IV collagen degradation (lcSSc: 36.1 ng/ml, dcSSc: 30.6 ng/ml).
type iii and Vi collagens correlates with mRSS. The levels of formation, degradation and turnover of 
type III, IV and VI collagens correlated with mRSS at first time point. Type III collagen formation (PRO-C3) and 
turnover (FICol3) showed the best correlations with Rho’s of 0.53 (P = 0.0003) and 0.59 (P < 0.0001), respec-
tively. Type VI collagen formation and turnover followed with Rho’s of 0.40 (P = 0.008) and 0.35 (P = 0.04), 
respectively. Type IV collagen formation and turnover did not correlate with mRSS (PRO-C4: Rho = −0.07, 
FICol4: Rho = 0.17). Collagen degradation biomarkers did not correlate with mRSS (C3M: Rho = −0.16, C4M: 
Rho = −0.14, C6M: Rho = 0.04).
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type iii collagen changes over time. Type III and VI collagens formation and turnover correlated mod-
erately with mRSS at a cross-sectional measure, and we were therefore interested in the changes over time. Serum 
samples at different time points were collected for each patient. However, patients did not have the same time 
points. MRSS was higher in dcSSc compared to lcSSc, especially at the beginning of the disease (Fig. 2). It reached 
a peak between 10 and 20 months where after it decreased. Type III collagen turnover furthermore observed a 
Healthy controls 
(n = 10)
Limited cutaneous 
SSc (n = 20)
Diffuse cutaneous 
SSc (n = 23)
Age, years 50 (9) 54 (14) 53 (16)
Female, % 7 (70) 16 (80) 18 (78)
BMI, kg/m2 24.4 (4.7) 24.8 (4.1)
Disease duration, months 32.3 (41.0) 13.5 (14.9)
MRSS 4.3 (3.1) 20.3 (11.7)
Organ involvement
Pulmonary fibrosis 11 (55) 9 (39)
Treatments
Calcium antagonist, % 9 (45) 8 (35)
ACE inhibitor, % 1 (5) 3 (13)
Iloprost, % 0 (0) 1 (4)
Prednisolone, % 3 (15) 6 (26)
Mycophenolate mophetil, % 1 (5) 0 (0)
Azathioprine, % 1 (5) 0 (0)
Methotrexate, % 1 (5) 0 (0)
Table 1. Baseline characteristics of limited and diffuse cutaneous SSc and healthy controls. BMI: Body mass 
index. mRSS: Modified Rodnan skin score. Data are shown as numbers (percent) or mean (standard deviation).
Figure 1. Fibrotic index of type III, IV, and VI collagens in limited and diffuse SSc. (a) cross-sectional view 
of the fibrotic index of type III collagen. (b) Cross-sectional view of the fibrotic index of type IV collagen. (c) 
Cross-sectional view of the fibrotic index of type VI collagen. Data are shown as mean. Data were analysed by 
the Mann-Whitney U test. *P < 0.05, **P < 0.01, ***P < 0.001.
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difference between lcSSc and dcSSc over time. DcSSc had high levels of type III collagen turnover at the begin-
ning, which steadily fell over the disease duration.
Discussion
In this study, we examined the blood levels of formation, degradation, and turnover of type III, IV, and VI colla-
gens metabolites and their relation to mRSS. We found that collagen turnover was better at separating SSc subsets 
than single collagen biomarkers and that type III and VI collagens, but not type IV collagen, correlated with 
mRSS. From these data, we argue that it is crucial to analyse collagen turnover and individual collagen types as 
type III, IV, and VI collagens.
This study analysed SSc patients according to their skin involvement, i.e., lcSSc and dcSSc. The dcSSc patients 
are known to have increased fibrosis, not only of the skin but also internal organs. This fits with our data showing 
increased collagen production in this patient subset. The dcSSc patients had increased type III and VI collagens 
turnover compared to lcSSc patients. We have previously examined the formation and degradation of collagens 
and seen that especially collagen formation is upregulated in SSc6,18. Increased skin thickness is likely due to 
increased collagen production. Both type III and VI collagens turnover correlated moderately to strongly with 
mRSS. The correlation supports the hypothesis that type III and VI collagens is related to skin fibrosis. The forma-
tion biomarkers of type III and VI collagens were also elevated in dcSSc patients and correlated moderately with 
mRSS. However, with increased formation, there might also be increased degradation, i.e., an overall higher turn-
over. We have previously shown that degradation biomarkers can be elevated in dcSSc patients6,19. We, therefore, 
argue that the collagen turnover gives a more accurate picture of the collagen deposition.
Type III and VI collagens are known to be in the interstitial matrix throughout the dermis20. Type IV collagen 
is found in the basement membrane around blood vessels and in the dermo-epidermal junction21. Contrary to 
type III and VI collagens, type IV collagen did not differ between lcSSc and dcSSc; it was elevated in both sub-
groups compared to controls. This indicates that type IV collagen turnover is overall elevated in SSc patients but 
not related to subtypes. Furthermore, type IV collagen turnover did not correlate with mRSS. A hallmark of SSc 
is vascular damage, especially microangiopathy22. Type IV collagen remodelling is affected by constant vascular 
damage. As vascular damage is found in both lcSSc and dcSSc, it might explain the increase of type IV collagen 
turnover in both lcSSc and dcSSc compared to controls. Type IV collagen has previously been shown upregulated 
in SSc by Motegi and colleagues23. They found that type IV collagen was elevated in patients with three years 
of disease duration or less. This corresponds well with our findings as our average disease duration was below 
three years. We have previously shown that type IV collagen formation and degradation were elevated in dcSSc 
patients compared to controls, especially in early SSc (<2 years of disease duration)6. Overall, these three studies 
show that there is an increased amount of type IV collagen with SSc and that its potential and meaning should be 
further examined.
Longitudinal samples showed a trend for type III collagen turnover to change over time in dcSSc. This indi-
cates that type III collagen changes throughout the disease and could offer insight into the pathogenesis. It was 
increased in the first 20 months of the disease, similar to mRSS. However, instead of having a peak, the levels 
steadily fell over the disease course. Type III collagen turnover, therefore, shows that serologically measured 
biomarkers could help understand the changes in disease over time. These data are preliminary and needs to be 
validated.
The limitations of this study include that different treatments may have affected biomarker levels. Nevertheless, 
analysis of type III collagen turnover mirrored the widely used clinical readout mRSS throughout the disease.
In conclusion, type III and VI collagens are correlated with mRSS and elevated in dcSSc patients. Type III 
collagen furthermore changes over time, indicating that especially type III collagen turnover can be used as a bio-
marker of skin fibrosis. Type IV collagen turnover is not related to mRSS but elevated in SSc patients, suggesting 
that it might be useful for vascular involvement and not skin fibrosis. Collagen turnover might have additional 
power compared to only looking at formation or degradation biomarkers. This opens the field for following 
patients with serological biomarkers.
Data availability
The datasets generated during and/or analysed during the current study are available from the corresponding 
author on reasonable request.
Figure 2. Modified Rodnan skin score and the fibrotic index of type III collagen in lcSSc and dcSSc. Data are 
shown as mean. Data were analysed by Generalized Additive Mixed Models15.
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